Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - furosemide, quantity: 500 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; lactose monohydrate; silicon dioxide; maltodextrin - indications as at 01 jan 1991 : frusemide in a high-dosage formulation such as urex forte ( 500 mg tablets ) is intended exclusively for patients with severely impaired renal function. for use under strict medical supervision only within a hospital setting (see dosage and administration). high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function e.g. in chronic glomerulonephritis, lupus erythematous and kimmelstiel-wilson syndrome. if diuresis is less than 2.5 l / day dialysis has to be used.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - furosemide, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch - indications as at 01 jan 1991 : oedema : in adults, infants and children frusemide is indicated for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver, renal disease including nephrotic syndrome and other oedematous states amenable to diuretic therapy. hypertension : may also be used alone in the control of mild to moderate hypertension and in combination with other antihypertensive agents in the treatment of more severe cases. studies have shown that frusemide is either less effective than or equally effective as thiazide diuretics in uncomplicated hypertension. however, in patients with severe renal function impairment, a diuretic and antihypertensive response to frusemide may be achieved while thiazides have no effect.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - furosemide (frusemide) -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - furosemide, quantity: 40 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch - indications as at 01 jan 1991 : oedema : in adults, infants and children frusemide is indicated for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver, renal disease including nephrotic syndrome and other oedematous states amenable to diuretic therapy. hypertension : may also be used alone in the control of mild to moderate hypertension and in combination with other antihypertensive agents in the treatment of more severe cases. studies have shown that frusemide is either less effective than or equally effective as thiazide diuretics in uncomplicated hypertension. however, in patients with severe renal function impairment, a diuretic and antihypertensive response to frusemide may be achieved while thiazides have no effect.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - furosemide (frusemide) -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - furosemide (frusemide) -

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - furosemide, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; nitrogen; sodium chloride - oedema: furosemide ? aft is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. it is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.,furosemide ? aft injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset of diuresis is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, furosemide ? aft is indicated by the intravenous route. parenteral use should be replaced with oral furosemide as soon as practical.

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - famciclovir, quantity: 500 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; sodium starch glycollate; titanium dioxide; hypromellose; macrogol 6000; macrogol 4000 - elovax is indicated for the treatment of herpes zoster infection in adult patients who commence therapy within 72 hours of the onset of the rash. greatest benefit occurs if the drug is started within 48 hours. efficacy has not been demonstrated in patients less than 50 years of age, although the occasional younger patient with severe herpes zoster may benefit from therapy with famciclovir. herpes zoster is generally a milder condition in younger patients. elovax is also indicated in the treatment of recurrent episodes of genital herpes in adults and adolescents 12 years of age and older. elovax is also indicated for suppression of recurrent genital herpes. elovax is also indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent patients elovax is also indicated in immunocompromised patients for: treatment of uncomplicated herpes zoster; treatment of recurrent herpes simplex; suppression of recurrent herpes simplex.

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - famciclovir, quantity: 250 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; lactose; sodium starch glycollate; titanium dioxide; hypromellose; macrogol 6000; macrogol 4000 - elovax is indicated for the treatment of herpes zoster infection in adult patients who commence therapy within 72 hours of the onset of the rash. greatest benefit occurs if the drug is started within 48 hours. efficacy has not been demonstrated in patients less than 50 years of age, although the occasional younger patient with severe herpes zoster may benefit from therapy with famciclovir. herpes zoster is generally a milder condition in younger patients. elovax is also indicated in the treatment of recurrent episodes of genital herpes in adults and adolescents 12 years of age and older. elovax is also indicated for suppression of recurrent genital herpes. elovax is also indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent patients elovax is also indicated in immunocompromised patients for: treatment of uncomplicated herpes zoster; treatment of recurrent herpes simplex; suppression of recurrent herpes simplex.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - famciclovir -